EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP‐00)

Liam D King iD, David Christie iD, Daniel Cehic, Wendy Dare, Russ Chess-Williams, Donna Sellers iD, Catherine McDermott, Alexandra McCarthy, Shailendra Anoopkumar-Dukie

The Prostate · 2026-06 · 86 (8) · 891-899

DOI: 10.1002/pros.70162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 15.03.2026. Verfasst von Liam D King und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prazosin, Adrenergic alpha-1 Receptor Antagonists, Drug Repositioning. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GenesisCare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Further work is needed to improve treatment outcomes for prostate cancer (PCa), with the repurposing of the α 1 ‐adrenoreceptor antagonists presenting a potential solution. This feasibility clinical trial presents the first prospective data of the use of an α 1 ‐adrenoreceptor antagonist in men undergoing radiotherapy for PCa.

Methods

The study enrolled men planned to receive radiotherapy for PCa. Participants received escalating doses of prazosin administered during radiotherapy. Blood pressure was recorded at each radiotherapy fraction. The primary outcome was treatment protocol feasibility and secondary outcomes were maximum tolerated dose (MTD) of prazosin, safety, and progression‐free survival (PFS).

Results

Ten participants were enrolled into the study and all achieved > 90% treatment compliance and > 80% assessment compliance. One participant and four participants achieved an MTD of 1 mg and 0.5 mg, respectively, and the remaining five participants had an MTD of 0 mg, with the overall protocol defined MTD being 0 mg. There were no Grades 3/4 adverse events. All treatment‐related adverse events (TRAE) were either hypotension or orthostatic hypotension, of the 17 reported TRAEs 16 were asymptomatic. No participants had evidence of disease progression at the 36‐week follow‐up.

Conclusions

Our study demonstrated that coadministration of prazosin during radiotherapy is feasible. However, the incidence of hypotension resulted in a protocol‐defined MTD (under conservative blood pressure based DLT definition) of 0 mg, although 16 of the 17 reports were asymptomatic. Combined with monitoring used in other studies utilizing prazosin, this suggests that our safety monitoring and dose‐limiting toxicity (DLT) definition may have been too strict and did not accurately reflect a clinically relevant MTD. As this study achieved its primary aim and demonstrated the feasibility of the administration of prazosin during radiotherapy, further prospective studies are justified, with greater consideration given to the definition of DLTs. Trial Registration Australian New Zealand Clinical Trials Registry (381954).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPrazosinAdrenergic alpha-1 Receptor AntagonistsDrug RepositioningHumansMaleFeasibility StudiesAgedMiddle AgedTreatment OutcomeProspective StudiesMaximum Tolerated DoseProgression-Free Survival

Stichwörter der Autor:innen

drug repurposingprazosinprostate cancerradiotherapyα1‐adrenoreceptor antagonist

Substanzen

PrazosinAdrenergic alpha-1 Receptor Antagonists

Autor:innen und Institutionen

  • School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia.
  • GenesisCare, Gold Coast, Queensland, Australia.
  • Advara HeartCare, Adelaide, South Australia, Australia.
  • University of Adelaide, Adelaide, South Australia, Australia.
  • Ramsay Pharmacy Group, Melbourne, Victoria, Australia.
  • Faculty of Health Science and Medicine, Bond University, Gold Coast, Queensland, Australia.

ORCID-Profile: Liam D King, David Christie, Donna Sellers

Förderung

  • GenesisCare

Zitieren

APA

King, L. D., Christie, D., Cehic, D., Dare, W., Chess-Williams, R., Sellers, D., McDermott, C., McCarthy, A., & Anoopkumar-Dukie, S. (2026). A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP‐00). The Prostate, 86(8), 891-899. https://doi.org/10.1002/pros.70162

Vancouver

King LD, Christie D, Cehic D, Dare W, Chess-Williams R, Sellers D, et al. A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP‐00). The Prostate. 2026;86(8):891-899. doi:10.1002/pros.70162

BibTeX
@article{King2026,
  author = {King, Liam D and Christie, David and Cehic, Daniel and Dare, Wendy and Chess-Williams, Russ and Sellers, Donna and McDermott, Catherine and McCarthy, Alexandra and Anoopkumar-Dukie, Shailendra},
  title = {A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP‐00)},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {8},
  pages = {891--899},
  doi = {10.1002/pros.70162}
}
Kostenlos starten →